September 30, 2016 1:15 AM ET

Capital Markets

Company Overview of Tekla Life Sciences Investors

Company Overview

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of b...

2 Liberty Square

9th Floor

Boston, MA 02109

United States

Founded in 1992





Key Executives for Tekla Life Sciences Investors

Principal Executive Officer, President, Trustee and Member of Valuation Committee
Age: 63
Principal Financial Officer, Chief Compliance Officer, Secretary and Treasurer
Age: 48
Assistant Treasurer
Age: 44
Compensation as of Fiscal Year 2016.

Tekla Life Sciences Investors Key Developments

Tekla Life Sciences Investors, Annual General Meeting, Jun 14, 2016

Tekla Life Sciences Investors, Annual General Meeting, Jun 14, 2016, at 10:00 US Eastern Standard Time. Location: 100 Federal Street, 19th Floor Boston, MA 02110 United States Agenda: To consider the election of trustees of fund; to consider the ratification or rejection of the selection of Deloitte & Touche LLP as the independent registered public accountants of fund for the fiscal year ending September 30, 2016; to consider change the subclassification of the company from ‘diversified’ to ‘non-diversified; and eliminate the related fundamental investment restriction; to amend the company’s fundamental investment restriction regarding issuing senior securities; to remove the company's fundamental investment restriction regarding investments in other investment companies; and to consider the transaction of such other business as may properly come before the annual meeting and any adjournment(s) or postponement(s) thereof.

Tekla Life Sciences Investors Declares Quarterly Dividend, Payable on June 10, 2016

Tekla Life Sciences Investors has declared a quarterly dividend of $0.37 per share, a 23% decline from its prior dividend of $0.48, and a 31% drop from its $0.54 dividend from the same quarter last year. The dividend for the management investment fund is payable on June 10 to shareholders of record as of April 25.

Tekla Life Sciences Investors Declares Special Cash Distribution, Payable on January 8, 2016

On December 18, 2015, Tekla Life Sciences Investors declared a special cash distribution of $0.71 per share in order to satisfy annual tax distribution requirements. The record date for the distribution is December 30, 2015 and the payable date is January 8, 2016. The Fund will trade ex-distribution on December 28, 2015.

Similar Private Companies By Industry

Company Name Region
@Visory LLC United States
1 Road Partners LLC United States
11T Partners, LLC United States, Inc. United States
1509225 Ontario, Inc. United States

Recent Private Companies Transactions

June 9, 2016
Afferent Pharmaceuticals, Inc.
Private Placement
June 2, 2016
Pieris Pharmaceuticals, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tekla Life Sciences Investors, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at